Latest Conference Articles

September 8th 2021, 7:25pm

IASLC World Conference on Lung Cancer

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

September 8th 2021, 6:49pm

IASLC World Conference on Lung Cancer

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

September 8th 2021, 6:42pm

IASLC World Conference on Lung Cancer

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

September 8th 2021, 6:35pm

Society of Hematologic Oncology Annual Meeting (SOHO)

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

September 8th 2021, 6:11pm

IASLC World Conference on Lung Cancer

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

September 8th 2021, 3:53pm

IASLC World Conference on Lung Cancer

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

September 7th 2021, 5:21pm

International Liver Cancer Association Annual Conference

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

September 7th 2021, 1:02pm

International Liver Cancer Association Annual Conference

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

September 5th 2021, 8:27pm

International Liver Cancer Association Annual Conference

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

September 5th 2021, 4:34pm

International Liver Cancer Association Annual Conference

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

September 5th 2021, 4:05pm

International Liver Cancer Association Annual Conference

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

September 5th 2021, 12:04am

International Liver Cancer Association Annual Conference

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

September 4th 2021, 4:04pm

International Liver Cancer Association Annual Conference

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

September 4th 2021, 4:02pm

International Liver Cancer Association Annual Conference

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

September 4th 2021, 4:01pm

International Liver Cancer Association Annual Conference

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

September 4th 2021, 3:55pm

The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.

September 4th 2021, 3:35pm

International Liver Cancer Association Annual Conference

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

September 3rd 2021, 10:57pm

International Liver Cancer Association Annual Conference

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

August 16th 2021, 1:13pm

ASCO Direct Highlights

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

August 13th 2021, 5:35pm

Pan Pacific Lymphoma Conference

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.